Despite having a good market, the pharmaceutical manufacturing in Vietnam still faces many difficulties. This difficulty comes from industry competition, world competition and technological development. In order for the pharmaceutical manufacturing to develop, what should pharmaceutical enterprises do?

Overview of Vietnam’s pharmaceutical industry

Overview of Vietnam’s pharmaceutical manufacturing industry 2023.
The market for the pharmaceutical industry in Vietnam is relatively active:
The pharmaceutical manufacturing industry in Vietnam is classified as a rapidly growing industry.
Especially in 2022, the pharmaceutical manufacturing industry witnessed remarkable growth. According to a general report, Vietnam’s pharmaceutical market is valued at about 6.2-6.4 billion USD/year. Vietnam’s pharmaceutical market is also forecast to reach 16.1 billion USD in 2026. According to VIRAC’s report, in the first quarter of 2023, the industrial production index of this industry group achieved a growth rate of nearly 7% over the same period last year.
Domestic pharmaceutical production is expanding in scale.
According to the latest report of VIRAC, Vietnam has 51 foreign-invested pharmaceutical enterprises. 228 enterprises met WHO – GMP standards. 18 enterprises meet high GMP standards such as EU, PICs, JAPAN, TCA. 03 facilities with PIC/S-GMP production lines.
The above figures show that Vietnam’s pharmaceutical manufacturing industry has really made quite a step forward. Pharmaceutical manufacturing enterprises invest more, achieve better manufacturing practice standards. Moreover, the pharmaceutical distribution system in Vietnam is relatively developed. In particular, the drugstore system is developing widely across the country.

Limitations of the pharmaceutical industry in Vietnam.
It can be said that the pharmaceutical market in Vietnam is developing very well. However, the pharmaceutical industry in Vietnam still has many limitations.
Limit 1: The pharmaceutical industry lacks connection with advanced technology and techniques.
Many drug factories in Vietnam only produce pharmaceutical products with simple production lines. Factories also focus on generic drugs, which are bioequivalent to invention drugs (generic drugs). The reason is that the production plants lack connection with modern technology, new preparation techniques,…It is sad that more than 90% of raw materials for domestic pharmaceutical production have to be imported.

Pharmaceutical manufacturing industry lacks connection to advanced technology and techniques

Limit 2: The pharmaceutical industry has not yet mastered the Vietnamese market
Such a good consumption market, Vietnam’s pharmaceutical market is still a “playground” for foreign businesses. In the period from 2015 to 2021, the value of domestic pharmaceutical production is still low. This figure only reached 46% of the total value of drug use of the people.
This rate has increased significantly compared to the previous period (2001-2011) but is still low compared to the world. The reason is that the pharmaceutical industry in Vietnam has not been able to produce specific products. Most of the drugs produced in the country are only used to treat common and chronic diseases.
Top 10 prestigious pharmaceutical manufacturing companies in Vietnam, 2022
Some Vietnamese enterprises have partly overcome the above limitations. These enterprises have applied technology in production to become one of the top 10 prestigious pharmaceutical manufacturing companies in Vietnam in 2022, according to a report by VIRAC.

Companies applying technology to production

1- Hau Giang Pharmaceutical Joint Stock Company
2- Traphaco Joint Stock Company
3- Sanofi – Aventis Vietnam Co., Ltd
4- Imexpharm Pharmaceutical Joint Stock Company
5- Binh Dinh Pharmaceutical – Medical Equipment Joint Stock Company
6- Pymepharco Joint Stock Company
7- Domesco Medical Import-Export Joint Stock Company
8- TV Pharm Pharmaceutical Joint Stock Company
9- OPC Pharmaceutical Joint Stock Company
10- Ha Tay Pharmaceutical Joint Stock Company

Direction for enterprises in the pharmaceutical industry
With the existing consumption market, pharmaceutical enterprises in Vietnam need to improve their competitiveness with foreign enterprises.

The first direction for pharmaceutical manufacturing enterprises: To stay ahead of technology:
Up to now, when the need for essential therapeutic drugs is essential, the basic is usually covered. Therefore, the pharmaceutical industry needs to focus its resources on the more difficult stages of the pharmaceutical industry. For example, research, testing, development, production of specialized drugs, special treatments, rare drugs, invention drugs… This will help businesses reduce dependence on foreign medicinal products.

Technology is an important factor for the development of the pharmaceutical industry

Advanced technology is always the key when it comes to growth and competitiveness. Therefore, pharmaceutical manufacturing enterprises need to apply advanced science and technology to production. However, applying advanced technology to production is a relatively difficult task for small and medium enterprises. Therefore, leading large enterprises in the industry need to be pioneers in the development and application of science and technology to production.

Take advantage of available potentials and strengths:
On the other hand, businesses need to apply technology to fully exploit the inherent strengths of our country. It is a rich source of medicinal herbs and high-quality human resources in the country. In order to raise the ranking of Vietnam’s pharmaceutical industry on the world map, pharmaceutical manufacturers must “take shortcuts, catch up” with technology and bring into full play the capacity of the pharmaceutical industry. In particular, it is necessary to promote investment in research, testing and development of biological drugs, invention drugs….

Reduce competition among enterprises by dividing industry groups:
Generic drug market share is already small, plus many companies produce together, leading to fierce competition. This leads to inefficient production and business activities of enterprises. It is this that makes Vietnamese businesses lack competitiveness with businesses in the world.
Therefore, it is necessary to divide each pharmaceutical manufacturing enterprise into a different product niche. This will reduce competition among domestic enterprises and diversify products. By doing this, Vietnam’s pharmaceutical industry will have more competitiveness with foreign enterprises.

Source: VIRAC


Stellapharm is one of leading generics pharmaceutical companies and strong producer of anti-viral drugs in Vietnam. The company established in Vietnam in 2000; and focuses on both prescription drugs and non-prescription especially in cardiovascular diseases, antiviral drugs, anti-diabetics drugs, etc. and our products are now used by millions of patients in more than 50 countries worldwide.

The company is globally recognized for its quality through our facilities have been audited and approved by stringent authority like EMA, PMDA, Taiwan GMP, local WHO and others.

Additional information for this article: Stellapharm J.V. Co., Ltd. – Branch 1
A: 40 Tu Do Avenue, Vietnam – Singapore Industrial Park, An Phu Ward, Thuan An City, Binh Duong Province, Vietnam
T: +84 274 376 7470 | F: +84 274 376 7469 | E: info@stellapharm.com | W: www.stellapharm.com

You May like

19 Jun 2024


With the development of the global economy, the growth of the total population and the aging of society, the demand for drugs is increasing, and the market size of the global pharmaceutical industry will maintain growth. stable.In 2023, the total global pharmaceutical market is estimated to be approximately US$1,6 trillion. This is an increase of

13 Jun 2024


According to the Resolution, the Government of Vietnam highly appreciates the Ministry of Health of Vietnam for taking charge and cooperating with ministries and central authorities in actively preparing and presenting Bills according to the Law on Promulgation of Legislative Documents 2015; and Agrees on the necessity of the development of the Law on amendments